Yesterday’s limitations are tomorrow’s opportunities. Contribute to knowledge bases, find signatures, and research elusive new cancer mutations with whole exome sequencing tools by IDT. With the most complete coverage, established quality metrics, and a broad range of customizable solutions, IDT’s whole exome sequencing (WES) solutions offer greater confidence for cancer researchers.
In this multi-session virtual event, attendees will:
Director of Technical Development
McDonnell Genome Institute
Bob joined MGI in 1994 and has over 25 years of experience in the field of DNA sequencing and analysis. Throughout his time at MGI, he has led production-based targeted sequence efforts as well as the sequence improvement (finishing) pipelines responsible for genome sequence refinement.
Director of R&D
Geneseeq
Dr. Bao is responsible for the development of new NGS testing products, computational methods, and mathematical modelling in cancer genomics. Dr. Bao holds more than 10 patents and has published numerous papers in peer reviewed journals, including Gut, Journal of Thoracic Oncology, Clinical Cancer Research, Oncogene, and Bioinformatics. He is also an active member of ASCO and AACR.
Head of Laboratory—NGS Diagnostics Center
UK Aachen
Dr. Begermann received his undergraduate degree in biology from the Heinrich Heine University, Düsseldorf, Germany and Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen. He later completed his thesis on human molecular genetics/epigentics with a focus on imprinting disorders like Silver-Russel syndrome. He then completed post-doctoral research at the Institute of Human Genetics, RWTH Aachen University Hospital.
Director of Customer Success and Lead Scientist
Emedgene
Highly experienced and well-published researcher in the genetics of rare diseases. Led a research lab in Sheba Tel Hashomer where he took overall responsibility for budgeting, grant submission, and operational and scientific management. Heads customer success, scientific product development, and scientific collaborations at Emedgene.
VP of Bioinformatics and Biostatistics
M2GEN
Oliver leads the bioinformatics team and is building the biostatistics team to support the Avatar project, as well as collaborative projects between M2GEN, Pharma, and ORIEN partners. Prior to joining M2GEN, he led the Platform Informatics team within the Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center.
Head of Regulatory Genomics
The Institute of Human Genetics Aachen
Dr. Kraft has held two post-doctoral positions, one at the Institute of Immunology Jena, where he investigated mast cell signaling, and the other at the Institute of Human Genetics Aachen, where he is studying the molecular cause of rare inherited diseases through WES, WGS, nanopore sequencing, and basic molecular techniques. Prior to these roles, Dr. Kraft studied biochemistry and molecular biology at the Friedrich-Schiller-Universität Jena and completed his thesis and PhD on cancer genetics at the Institute of Human Genetics Jena.
PhD Student
Faculty of Pharmaceutical Sciences, Ghent University
Laurentijn graduated from the Faculty of Bioscience Engineering of Ghent University in 2016. He is now working on his PhD at the Faculty of Pharmaceutical Sciences of Ghent University in the core facility for next-generation sequencing (NXTGNT). His primary focus is on sequencing analysis in the field of pharmacogenomics.